Methods and compositions for inhibiting ADAM 9 biological activities
AssigneeVerra Therapeutics, Inc.
InventorsMarcia L. Moss, Robert Rasmussen, Chris Prince
Life of this patent
Estimating the term…
Abstract
Provided are ADAM9 modulating peptides and methods for using the same to modulate ADAM9 biological activities in vitro and/or in vivo, to inhibit ADAM9 biological activities associated with diseases or disorders in subjects, to decrease inflammation, and to inhibit undesirable cellular proliferation, fibrosis, and angiogenesis. In some embodiments, the ADAM9 modulating peptides include modifications of one or more amino acids of the human ADAM9 prodomain amino acid sequence, and in some embodiments the ADAM9 modulating peptides include other modifications such as but not limited to the addition of PEG groups.
Claims21
A peptide comprising SEQ ID NO:
- 3, wherein relative to the amino acid sequence set forth in SEQ ID NO:
- 2, the peptide includes one or more amino acid substitutions and/or chemical modifications at amino acid position(s) 85, 104, and 146, wherein the substitution(s) are selected from substitution of the cysteine with serine, alanine, or glycine.
A peptide comprising an amino acid sequence having at least 87% sequence identity to the full-length sequence of SEQ ID NO:
- 13, wherein relative to the amino acid sequence set forth in SEQ ID NO:
- 2, the peptide includes an amino acid substitution and/or modification at amino acid position(s) 85, 104, and 146.
A peptide comprising an amino acid sequence having at least 95% sequence identity to the full-length sequence of SEQ ID NO:
- 13, wherein relative to the amino acid sequence set forth in SEQ ID NO:
- 2, the peptide includes an amino acid substitution and/or modification at amino acid position(s) 85, 104, and 146.
A peptide comprising 100% sequence identity to SEQ ID NO:
- 13 over its full length.
A peptide fragment comprising amino acids 7-174 of SEQ ID NO:
- 3, wherein as compared to SEQ ID NO:
- 2, the amino acid sequence of the fragment comprises an alanine at amino acid 27;
- serines at amino acids 85, 104, and 146;
- and the fragment does not comprise amino acids 1-6 of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.